
Opinion: The man behind ‘value-based pricing’ saw pharma distorting his message — and walked away
When Biogen announced the price for Aduhelm, its controversial Alzheimer’s drug, the explanation the company gave — it represented the “overall value this treatment brings to patients, caregivers and society” …
Read More